Johnson & Johnson(JNJ)Earnings, Financials & Key Ratios

JNJ•NYSE

$225.59

$543.64B mkt cap·39.0× P/E·Price updated May 6, 2026

SectorHealthcare IndustryLarge Pharma Sub-IndustryLarge diversified branded pharma

AboutJohnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.Show more

Revenue$88.82B+4.3%
EBITDA$29.49B-4.6%
Net Income$14.07B-60.0%
EPS (Diluted)5.79-57.8%
Gross Margin69.07%+0.4%
EBITDA Margin33.2%-8.5%
Operating Margin24.94%-9.3%
Net Margin15.84%-61.6%
ROE20.06%-58.5%
ROIC20.73%+6.2%
Debt/Equity0.51+20.1%
Interest Coverage29.34-3.3%

Analysis→Technical→

JNJ Key Insights

Johnson & Johnson (JNJ) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Dividend Aristocrat: 36 years of consecutive increases
✓Excellent 3Y average ROE of 30.7%
✓FCF machine: 22.3% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Healthy dividend yield of 2.2%
✓Share count reduced 5.1% through buybacks

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

JNJ Price & Volume

Johnson & Johnson (JNJ) stock price & volume — 10-year historical chart

Loading chart...

JNJ Growth Metrics

Johnson & Johnson (JNJ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years1.8%

5 Years1.6%

3 Years4.1%

TTM3.75%

Profit CAGR

10 Years-1.48%

5 Years-1.43%

3 Years-12.33%

TTM78.58%

EPS CAGR

10 Years0.16%

5 Years0.56%

3 Years-9.49%

TTM78.93%

Return on Capital

10 Years16.91%

5 Years16.58%

3 Years17.27%

Last Year17.64%

JNJ Recent Earnings

Johnson & Johnson (JNJ) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 11/12 qtrs (92%)●Beat Revenue 10/12 qtrs (83%)

Q2 2026Latest

Apr 14, 2026

EPS

$2.70

Est $2.68

+0.7%

Revenue

$24.1B

Est $23.6B

+1.9%

Q1 2026

Jan 21, 2026

EPS

$2.46

Est $2.46

+0.0%

Revenue

$24.6B

Est $24.1B

+1.7%

Q4 2025

Oct 14, 2025

EPS

$2.80

Est $2.76

+1.4%

Revenue

$24.0B

Est $23.8B

+1.0%

Q3 2025

Jul 16, 2025

EPS

$2.77

Est $2.68

+3.4%

Revenue

$23.7B

Est $22.9B

+3.9%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Apr 14, 2026	$2.70vs $2.68+0.7%	$24.1Bvs $23.6B+1.9%
Q1 2026	Jan 21, 2026	$2.46vs $2.46+0.0%	$24.6Bvs $24.1B+1.7%
Q4 2025	Oct 14, 2025	$2.80vs $2.76+1.4%	$24.0Bvs $23.8B+1.0%
Q3 2025	Jul 16, 2025	$2.77vs $2.68+3.4%	$23.7Bvs $22.9B+3.9%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
ABTAbbott LaboratoriesDirect Competitor	151.59B	87.18	11.41	4.59%	31.88%	27.26%	4.19%	0.32
PFEPfizer Inc.Direct Competitor	150.4B	26.44	19.44	-1.65%	11.83%	8.34%	6.03%	0.78
MRKMerck & Co., Inc.Direct Competitor	279.49B	113.16	15.54	1.18%	28.12%	36.14%	4.42%	0.96
LLYEli Lilly and CompanyDirect Competitor	933.66B	988.19	43.06	44.7%	34.98%	101.17%	0.96%	1.60
BMYBristol-Myers Squibb CompanyDirect Competitor	116.22B	56.92	16.50	-0.22%	15.01%	38.96%	11.05%	2.55
ABBVAbbVie Inc.Direct Competitor	364.63B	206.15	86.98	8.57%	6.91%	62.15%	4.89%
NVSNovartis AGDirect Competitor	277.63B	145.50	20.24	5.97%	24.14%	31.42%	6.37%	0.80
SYKStryker CorporationProduct Competitor	113.08B	295.25	35.15	11.16%	12.92%	15.04%	3.79%	0.66

Compare JNJ vs Peers

Johnson & Johnson (JNJ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ABT

Most directly comparable listed peer for JNJ.

Scale Benchmark

vs LLY

Larger-name benchmark to compare JNJ against a more recognizable public peer.

Peer Set

Compare Top 5

vs ABT, PFE, MRK, LLY

JNJ Income Statement

Johnson & Johnson (JNJ) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	TTM
Sales/Revenue	71.89B	76.45B	81.58B	82.06B	82.58B	78.74B	79.99B	85.16B	88.82B	92.15B
Revenue Growth %	2.59%	6.34%	6.71%	0.59%	0.64%	-4.65%	1.59%	6.46%	4.3%	3.75%
Cost of Goods Sold	21.79B	25.44B	27.09B	27.56B	28.43B	23.4B	24.6B	26.55B	27.47B	29.42B
COGS % of Revenue	30.31%	33.28%	33.21%	33.58%	34.42%	29.72%	30.75%	31.18%	30.93%	-
Gross Profit	50.1B▲ 0%	51.01B▲ 1.8%	54.49B▲ 6.8%	54.5B▲ 0.0%	54.16B▼ 0.6%	55.34B▲ 2.2%	55.39B▲ 0.1%	58.61B▲ 5.8%	61.35B▲ 4.7%	62.73B▲ 0%
Gross Margin %	69.69%	66.72%	66.79%	66.42%	65.58%	70.28%	69.25%	68.82%	69.07%	68.08%
Gross Profit Growth %	3.22%	1.82%	6.82%	0.02%	-0.63%	2.18%	0.1%	5.8%	4.68%	-
Operating Expenses	29.21B	32.11B	33.31B	33.53B	34.42B	34.4B	34.38B	35.2B	39.2B	38.69B
OpEx % of Revenue	40.63%	42.01%	40.84%	40.86%	41.68%	43.68%	42.98%	41.33%	44.13%	-
Selling, General & Admin	20.07B	21.52B	22.54B	22.18B	22.08B	20.12B	20.25B	20.11B	21.97B	22.98B
SG&A % of Revenue	27.91%	28.15%	27.63%	27.03%	26.74%	25.55%	25.31%	23.62%	24.73%	-
Research & Development	9.14B	10.59B	10.78B	11.36B	12.34B	14.28B	14.13B	15.09B	17.23B	15.71B
R&D % of Revenue	12.72%	13.86%	13.21%	13.84%	14.94%	18.13%	17.67%	17.71%	19.4%	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income	20.89B▲ 0%	18.9B▼ 9.5%	21.18B▲ 12.1%	20.97B▼ 1.0%	19.73B▼ 5.9%	20.94B▲ 6.1%	21.01B▲ 0.3%	23.41B▲ 11.4%	22.15B▼ 5.4%	24.05B▲ 0%
Operating Margin %	29.06%	24.72%	25.96%	25.55%	23.89%	26.6%	26.27%	27.49%	24.94%	26.09%
Operating Income Growth %	14.23%	-9.54%	12.05%	-0.97%	-5.9%	6.13%	0.33%	11.4%	-5.38%	-
EBITDA	24.64B	24.54B	28.1B	27.98B	26.96B	28.33B	27.98B	30.89B	29.49B	31.43B
EBITDA Margin %	34.28%	32.1%	34.45%	34.1%	32.65%	35.98%	34.98%	36.28%	33.2%	34.11%
EBITDA Growth %	11.84%	-0.43%	14.53%	-0.44%	-3.63%	5.08%	-1.24%	10.41%	-4.55%	6.96%
D&A (Non-Cash Add-back)	3.75B	5.64B	6.93B	7.01B	7.23B	7.39B	6.97B	7.49B	7.34B	7.39B
EBIT	20.53B	18.61B	19B	17.65B	16.7B	19.36B	19.64B	15.83B	17.44B	32.17B
Net Interest Income	-358M	-549M	-394M	39M	-90M	-130M	214M	489M	577M	433M
Interest Income	368M	385M	611M	357M	111M	53M	490M	1.26B	1.33B	1.1B
Interest Expense	726M	934M	1B	318M	201M	183M	276M	772M	755M	667M
Other Income/Expense	-1.09B	-1.22B	-3.18B	-3.64B	-3.24B	-1.76B	-1.65B	-8.35B	-5.46B	7.46B
Pretax Income	19.8B▲ 0%	17.67B▼ 10.8%	18B▲ 1.8%	17.33B▼ 3.7%	16.5B▼ 4.8%	19.18B▲ 16.3%	19.36B▲ 0.9%	15.06B▼ 22.2%	16.69B▲ 10.8%	31.5B▲ 0%
Pretax Margin %	27.55%	23.12%	22.06%	21.12%	19.98%	24.36%	24.2%	17.69%	18.79%	34.19%
Income Tax	3.26B	16.37B	2.7B	2.21B	1.78B	1.38B	2.99B	1.74B	2.62B	6.38B
Effective Tax Rate %	16.48%	92.64%	15.01%	12.75%	10.81%	7.18%	15.44%	11.53%	15.71%	20.26%
Net Income	16.54B▲ 0%	1.3B▼ 92.1%	15.3B▲ 1076.7%	15.12B▼ 1.2%	14.71B▼ 2.7%	20.88B▲ 41.9%	17.94B▼ 14.1%	35.15B▲ 95.9%	14.07B▼ 60.0%	25.12B▲ 0%
Net Margin %	23.01%	1.7%	18.75%	18.42%	17.82%	26.52%	22.43%	41.28%	15.84%	27.26%
Net Income Growth %	7.34%	-92.14%	1076.69%	-1.16%	-2.68%	41.89%	-14.07%	95.94%	-59.99%	78.58%
Net Income (Continuing)	16.54B	1.3B	15.3B	15.12B	14.71B	17.8B	16.37B	13.33B	14.07B	25.12B
Discontinued Operations	0	0	0	0	0	3.08B	1.57B	21.83B	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	5.93▲ 0%	0.47▼ 92.1%	5.61▲ 1093.6%	5.63▲ 0.4%	5.51▼ 2.1%	7.81▲ 41.7%	6.73▼ 13.8%	13.72▲ 103.9%	5.79▼ 57.8%	10.34▲ 0%
EPS Growth %	8.21%	-92.07%	1093.62%	0.36%	-2.13%	41.74%	-13.83%	103.86%	-57.8%	78.93%
EPS (Basic)	6.08	0.48	5.75	5.74	5.59	7.93	6.83	13.88	5.84	-
Diluted Shares Outstanding	2.79B	2.75B	2.73B	2.68B	2.67B	2.67B	2.66B	2.56B	2.43B	2.43B
Basic Shares Outstanding	2.71B	2.68B	2.66B	2.63B	2.63B	2.63B	2.61B	2.53B	2.41B	2.43B
Dividend Payout Ratio	52.12%	687.92%	62.06%	65.59%	71.23%	52.84%	65.11%	33.48%	84.05%	-

JNJ Balance Sheet

Johnson & Johnson (JNJ) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	TTM
Total Current Assets	65.03B	43.09B	46.03B	45.27B	51.24B	60.98B	55.29B	53.49B	55.89B	54.61B
Cash & Short-Term Investments	41.91B	18.3B	19.69B	19.29B	25.18B	31.61B	22.28B	22.93B	24.52B	18.56B
Cash Only	18.97B	17.82B	18.11B	17.3B	13.98B	14.49B	12.89B	21.86B	24.11B	18.23B
Short-Term Investments	22.93B	472M	1.58B	1.98B	11.2B	17.12B	9.39B	1.07B	417M	331M
Accounts Receivable	11.7B	13.49B	14.1B	14.48B	13.58B	18.98B	16.91B	14.87B	18.93B	17.61B
Days Sales Outstanding	59.4	64.41	63.08	64.41	60	88	77.18	63.75	77.78	69.72
Inventory	8.14B	8.77B	8.6B	9.02B	9.34B	10.39B	10.27B	11.18B	12.44B	14.15B
Days Inventory Outstanding	136.42	125.76	115.86	119.48	119.98	162.01	152.38	153.7	165.34	163.36
Other Current Assets	0	0	950M	94M	0	-3.7B	5.83B	0	0	4.29B
Total Non-Current Assets	76.18B	114.22B	106.92B	112.45B	123.66B	121.04B	132.08B	114.06B	124.21B	138.21B
Property, Plant & Equipment	15.91B	17B	17.04B	17.66B	18.77B	18.96B	17.98B	19.9B	20.52B	53.38B
Fixed Asset Turnover	4.52x	4.50x	4.79x	4.65x	4.40x	4.15x	4.45x	4.28x	4.33x	3.16x
Goodwill	22.8B	31.91B	30.45B	33.64B	36.39B	35.25B	36.05B	36.56B	44.2B	48.05B
Intangible Assets	26.88B	53.23B	47.61B	47.64B	53.4B	46.39B	38.49B	34.17B	37.62B	48.74B
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	4.43B	4.97B	4.18B	5.7B	6.56B	10.22B	30.62B	14.15B	11.41B	16.52B
Total Assets	141.21B▲ 0%	157.3B▲ 11.4%	152.95B▼ 2.8%	157.73B▲ 3.1%	174.89B▲ 10.9%	182.02B▲ 4.1%	187.38B▲ 2.9%	167.56B▼ 10.6%	180.1B▲ 7.5%	192.82B▲ 0%
Asset Turnover	0.51x	0.49x	0.53x	0.52x	0.47x	0.43x	0.43x	0.51x	0.49x	0.49x
Asset Growth %	5.84%	11.4%	-2.76%	3.12%	10.88%	4.07%	2.94%	-10.58%	7.49%	35.05%
Total Current Liabilities	26.29B	30.54B	31.23B	35.96B	42.49B	45.23B	55.8B	46.28B	50.32B	50.87B
Accounts Payable	6.92B	7.31B	7.54B	8.54B	9.51B	11.05B	9.89B	9.63B	10.31B	9.63B
Days Payables Outstanding	115.89	104.88	101.55	113.17	122.04	172.42	146.75	132.4	137	120.81
Short-Term Debt	4.68B	3.91B	2.8B	1.2B	2.63B	3.77B	12.76B	3.45B	5.98B	6.39B
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	971M	1.85B	818M	2.27B	3.48B	3.59B	6.64B	3.99B	4.13B	3.97B
Current Ratio	2.47x	1.41x	1.47x	1.26x	1.21x	1.35x	0.99x	1.16x	1.11x	1.11x
Quick Ratio	2.16x	1.12x	1.20x	1.01x	0.99x	1.12x	0.81x	0.91x	0.86x	0.86x
Cash Conversion Cycle	79.94	85.28	77.38	70.72	57.94	77.58	82.81	85.04	106.12	112.26
Total Non-Current Liabilities	44.5B	66.61B	61.97B	62.29B	69.12B	62.77B	54.77B	52.5B	58.29B	62.67B
Long-Term Debt	22.44B	30.68B	27.68B	26.49B	32.63B	29.98B	26.89B	25.88B	30.65B	39.41B
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	2.91B	8.37B	7.51B	5.96B	7.21B	7.49B	3.99B	3.19B	2.45B	14.66B
Other Non-Current Liabilities	19.15B	27.56B	26.78B	29.84B	29.27B	25.3B	23.89B	23.43B	25.19B	78.05B
Total Liabilities	70.79B	97.14B	93.2B	98.26B	111.62B	108B	110.57B	98.78B	108.61B	113.54B
Total Debt	27.13B	34.58B	30.48B	27.7B	35.27B	33.75B	39.64B	29.33B	36.63B	45.8B
Net Debt	8.15B	16.76B	12.37B	10.39B	21.28B	19.26B	26.75B	7.47B	12.53B	27.56B
Debt / Equity	0.39x	0.57x	0.51x	0.47x	0.56x	0.46x	0.52x	0.43x	0.51x	0.51x
Debt / EBITDA	1.10x	1.41x	1.08x	0.99x	1.31x	1.19x	1.42x	0.95x	1.24x	1.46x
Net Debt / EBITDA	0.33x	0.68x	0.44x	0.37x	0.79x	0.68x	0.96x	0.24x	0.42x	0.42x
Interest Coverage	28.78x	20.23x	21.07x	65.94x	98.17x	114.44x	76.13x	30.32x	29.34x	48.23x
Total Equity	70.42B▲ 0%	60.16B▼ 14.6%	59.75B▼ 0.7%	59.47B▼ 0.5%	63.28B▲ 6.4%	74.02B▲ 17.0%	76.8B▲ 3.8%	68.77B▼ 10.5%	71.49B▲ 3.9%	79.28B▲ 0%
Equity Growth %	-1.03%	-14.57%	-0.68%	-0.47%	6.4%	16.98%	3.76%	-10.46%	3.95%	38.19%
Book Value per Share	25.25	21.91	21.90	22.16	23.69	27.68	28.83	26.86	29.43	32.64
Total Shareholders' Equity	70.42B	60.16B	59.75B	59.47B	63.28B	74.02B	76.8B	68.77B	71.49B	79.28B
Common Stock	3.12B	3.12B	3.12B	3.12B	3.12B	3.12B	3.12B	3.12B	3.12B	3.12B
Retained Earnings	110.55B	101.79B	106.22B	110.66B	113.89B	123.06B	128.34B	153.84B	155.79B	167.28B
Treasury Stock	-28.35B	-31.55B	-34.36B	-38.42B	-38.49B	-39.1B	-41.69B	-75.66B	-75.68B	-75.89B
Accumulated OCI	-14.9B	-13.2B	-15.22B	-15.89B	-15.24B	-13.06B	-12.97B	-12.53B	-11.74B	-15.24B
Minority Interest	0	0	0	0	0	0	0	0	0	0

JNJ Cash Flow Statement

Johnson & Johnson (JNJ) cash flow — operating, investing & free cash flow history

Line item	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	TTM
Cash from Operations	18.77B	21.06B	22.2B	23.42B	23.54B	23.41B	21.19B	22.79B	24.27B	24.27B
Operating CF Margin %	26.11%	27.54%	27.21%	28.54%	28.5%	29.73%	26.5%	26.76%	27.32%	-
Operating CF Growth %	-2.66%	12.2%	5.44%	5.47%	0.51%	-0.54%	-9.47%	7.54%	6.47%	-13.5%
Net Income	16.54B	1.3B	15.3B	15.12B	14.71B	20.88B	17.94B	13.33B	14.07B	25.12B
Depreciation & Amortization	3.75B	5.64B	6.93B	7.01B	7.23B	7.39B	6.97B	7.49B	7.34B	7.39B
Stock-Based Compensation	878M	962M	978M	977M	1B	1.14B	1.14B	1.16B	1.18B	1.28B
Deferred Taxes	-341M	2.41B	-1.02B	-2.48B	-1.14B	-2.08B	-1.66B	-4.19B	-2.18B	5.2B
Other Non-Cash Items	-291M	-495M	10M	-1.08B	-963M	324M	819M	2.5B	2.03B	-15.58B
Working Capital Changes	-1.77B	11.24B	3M	3.87B	2.69B	-4.24B	-4.01B	2.51B	1.84B	798M
Change in Receivables	-1.06B	-633M	-1.19B	-289M	774M	-2.4B	-1.29B	-624M	-406M	-1.32B
Change in Inventory	-249M	581M	-644M	-277M	-265M	-1.25B	-2.53B	-1.32B	-1.13B	-1.49B
Change in Payables	-39.2B	2.73B	-12.97B	4.06B	5.14B	2.44B	1.1B	2.35B	1.62B	19M
Cash from Investing	-4.76B	-14.87B	-3.17B	-6.19B	-20.82B	-8.68B	-12.37B	878M	-18.6B	-20.42B
Capital Expenditures	-3.23B	-3.28B	-3.67B	-3.5B	-3.35B	-3.65B	-4.01B	-4.54B	-4.42B	-4.61B
CapEx % of Revenue	4.49%	4.29%	4.5%	4.26%	4.05%	4.64%	5.01%	5.33%	4.98%	-
Acquisitions	-4.51B	-35.15B	-899M	-5.81B	-7.32B	-60M	-17.65B	0	-15.15B	-14.46B
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	1.14B	1.6B	2.74B	3.31B	-1.2B	417M	65M	-3.06B	235M	-2.15B
Cash from Financing	-8.55B	-7.67B	-18.51B	-18.02B	-6.12B	-14.05B	-8.87B	-15.82B	-3.13B	-5.51B
Debt Issued (Net)	7.88B	6.75B	-3.95B	-2.88B	7.09B	-990M	7.45B	-2.73B	10.05B	7.1B
Equity Issued (Net)	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-2M
Dividends Paid	-8.62B	-8.94B	-9.49B	-9.92B	-10.48B	-11.03B	-11.68B	-11.77B	-11.82B	-12.23B
Share Repurchases	-8.98B	-6.36B	-5.87B	-6.75B	-3.22B	-3.46B	-6.04B	-5.05B	-2.43B	-2.41B
Other Financing	1.17B	874M	801M	1.53B	487M	1.43B	1.39B	-508M	1.07B	5.95B
Net Change in Cash	5.24B▲ 0%	-1.15B▼ 121.9%	283M▲ 124.7%	-802M▼ 383.4%	-3.32B▼ 314.0%	502M▲ 115.1%	-360M▼ 171.7%	7.73B▲ 2247.8%	2.25B▼ 71.0%	-1.75B▲ 0%
Free Cash Flow	15.54B▲ 0%	17.78B▲ 14.4%	18.53B▲ 4.2%	19.92B▲ 7.5%	20.19B▲ 1.4%	19.76B▼ 2.1%	17.18B▼ 13.0%	18.25B▲ 6.2%	19.84B▲ 8.7%	19.06B▲ 0%
FCF Margin %	21.62%	23.25%	22.71%	24.27%	24.45%	25.09%	21.48%	21.43%	22.34%	20.69%
FCF Growth %	-1.74%	14.39%	4.24%	7.48%	1.36%	-2.13%	-13.02%	6.19%	8.74%	5.57%
FCF per Share	5.57	6.48	6.79	7.42	7.56	7.39	6.45	7.13	8.17	8.17
FCF Conversion (FCF/Net Income)	1.13x	16.20x	1.45x	1.55x	1.60x	1.12x	1.18x	0.65x	1.73x	0.76x
Interest Paid	730M	960M	1.05B	995M	841M	941M	933M	1.77B	1.91B	0
Taxes Paid	2.84B	3.31B	4.57B	4.19B	4.62B	4.77B	5.22B	8.57B	6.71B	0

JNJ Key Ratios

Johnson & Johnson (JNJ) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	TTM
Return on Equity (ROE)	23.37%	1.99%	25.51%	25.36%	23.97%	30.41%	23.79%	48.29%	20.06%	31.69%
Return on Invested Capital (ROIC)	20.11%	18.23%	21.31%	22.15%	19.17%	17.66%	16.01%	19.53%	20.73%	20.73%
Gross Margin	69.69%	66.72%	66.79%	66.42%	65.58%	70.28%	69.25%	68.82%	69.07%	68.08%
Net Margin	23.01%	1.7%	18.75%	18.42%	17.82%	26.52%	22.43%	41.28%	15.84%	27.26%
Debt / Equity	0.39x	0.57x	0.51x	0.47x	0.56x	0.46x	0.52x	0.43x	0.51x	0.51x
Interest Coverage	28.78x	20.23x	21.07x	65.94x	98.17x	114.44x	76.13x	30.32x	29.34x	48.23x
FCF Conversion	1.13x	16.20x	1.45x	1.55x	1.60x	1.12x	1.18x	0.65x	1.73x	0.76x
Revenue Growth	2.59%	6.34%	6.71%	0.59%	0.64%	-4.65%	1.59%	6.46%	4.3%	3.75%

JNJ SEC Filings & Documents

Johnson & Johnson (JNJ) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 14, 2026·SEC

Material company update

Jan 21, 2026·SEC

Material company update

Oct 14, 2025·SEC

10-K Annual Reports

FY 2026

Feb 11, 2026·SEC

FY 2025

Feb 13, 2025·SEC

10-Q Quarterly Reports

FY 2025

Oct 22, 2025·SEC

FY 2025

Jul 24, 2025·SEC

FY 2025

Apr 23, 2025·SEC

JNJ Frequently Asked Questions

Johnson & Johnson (JNJ) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Johnson & Johnson (JNJ) reported $92.15B in revenue for fiscal year 2024. This represents a 389% increase from $18.84B in 1995.

Johnson & Johnson (JNJ) grew revenue by 4.3% over the past year. Growth has been modest.

Yes, Johnson & Johnson (JNJ) is profitable, generating $25.12B in net income for fiscal year 2024 (15.8% net margin).

Dividend & Returns

Yes, Johnson & Johnson (JNJ) pays a dividend with a yield of 2.16%. This makes it attractive for income-focused investors.

Johnson & Johnson (JNJ) has a return on equity (ROE) of 20.1%. This is excellent, indicating efficient use of shareholder capital.

Johnson & Johnson (JNJ) generated $19.06B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More JNJ

Johnson & Johnson (JNJ) financial analysis — history, returns, DCA and operating performance tools

Full JNJ Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Johnson & Johnson(JNJ)Earnings, Financials & Key Ratios

JNJ Key Insights

✓Strengths

✗Weaknesses

JNJ Price & Volume

JNJ Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

JNJ Recent Earnings

JNJ Peer Comparison

Compare JNJ vs Peers

vs ABT

vs LLY

Compare Top 5

JNJ Income Statement

JNJ Balance Sheet

JNJ Cash Flow Statement

JNJ Key Ratios

JNJ SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

JNJ Frequently Asked Questions

Explore More JNJ

Full JNJ Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation